Corxel Pharmaceuticals closed a $287 million Series D to advance CX‑11, an oral small‑molecule GLP‑1 receptor agonist licensed from Vincentage, through ongoing U.S. Phase II obesity trials and planned global diabetes studies. Management said the financing will fund Phase II readouts, preparations for Phase III, and other cardiometabolic programs. Investors described the round as evidence of continued capital appetite for obesity therapeutics, especially oral GLP‑1 candidates that could compete with injectables. Corxel plans concurrent U.S. and international development tracks; success in late‑stage trials will determine partnering or commercial scale decisions.